Search research articles
Contact Us
Filters
Showing results (1-10 of 74) with videos related to
Page
of 8
Sort By:
British Journal of Clinical Pharmacology
|
April 16, 2020
Sustainability of costs of novel biologicals: Are we all heading for bankruptcy?
Robert Likic
British Journal of Clinical Pharmacology
|
May 23, 2025
Educate to medicate: A clinical pharmacologist's perspective
Robert Likic, Michael Rieder
British Journal of Clinical Pharmacology
|
February 13, 2021
Postvaccination anaphylaxis and mRNA-based SARS-CoV-2 vaccines-Much ado about nothing?
Robert Marcec, Robert Likic
British Journal of Clinical Pharmacology
|
February 5, 2024
The future is now, old man
Marko Lucijanic, Robert Likic
Medical Teacher
|
September 16, 2006
Benefits and drawbacks of implementation of PBL elements into a new course on applied pharmacotherapy
Robert Likic, Igor Francetic
Clinical Pharmacokinetics
|
July 22, 2022
Could Fluvoxamine Dose De-escalation Increase Treatment Compliance Without Sacrificing Efficacy in COVID-19 Patients?
Robert Marcec, Robert Likic
Postgraduate Medical Journal
|
August 10, 2021
Using Twitter for sentiment analysis towards AstraZeneca/Oxford, Pfizer/BioNTech and Moderna COVID-19 vaccines
Robert Marcec, Robert Likic
Postgraduate Medical Journal
|
April 16, 2026
Penicillin allergy de-labelling as an equity-promoting intervention in Europe: results from a distributional cost-effectiveness model
Iva Mikulic, Robert Likic
Therapeutic Advances in Infectious Disease
|
July 2, 2019
Experience with fosfomycin in the treatment of complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae
Luka Bielen, Robert Likic
Wiener Klinische Wochenschrift
|
March 20, 2004
Severe thrombocytopenia as a complication of acute Epstein-Barr virus infection
Robert Likic, Dusko Kuzmanic
Page
of 8
Search research articles
Search
Showing results (1-10 of 74) with videos related to
Sort By:
Page
of 8
British Journal of Clinical Pharmacology
|
April 16, 2020
Sustainability of costs of novel biologicals: Are we all heading for bankruptcy?
Robert Likic
British Journal of Clinical Pharmacology
|
May 23, 2025
Educate to medicate: A clinical pharmacologist's perspective
Robert Likic, Michael Rieder
British Journal of Clinical Pharmacology
|
February 13, 2021
Postvaccination anaphylaxis and mRNA-based SARS-CoV-2 vaccines-Much ado about nothing?
Robert Marcec, Robert Likic
British Journal of Clinical Pharmacology
|
February 5, 2024
The future is now, old man
Marko Lucijanic, Robert Likic
Medical Teacher
|
September 16, 2006
Benefits and drawbacks of implementation of PBL elements into a new course on applied pharmacotherapy
Robert Likic, Igor Francetic
Clinical Pharmacokinetics
|
July 22, 2022
Could Fluvoxamine Dose De-escalation Increase Treatment Compliance Without Sacrificing Efficacy in COVID-19 Patients?
Robert Marcec, Robert Likic
Postgraduate Medical Journal
|
August 10, 2021
Using Twitter for sentiment analysis towards AstraZeneca/Oxford, Pfizer/BioNTech and Moderna COVID-19 vaccines
Robert Marcec, Robert Likic
Postgraduate Medical Journal
|
April 16, 2026
Penicillin allergy de-labelling as an equity-promoting intervention in Europe: results from a distributional cost-effectiveness model
Iva Mikulic, Robert Likic
Therapeutic Advances in Infectious Disease
|
July 2, 2019
Experience with fosfomycin in the treatment of complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae
Luka Bielen, Robert Likic
Wiener Klinische Wochenschrift
|
March 20, 2004
Severe thrombocytopenia as a complication of acute Epstein-Barr virus infection
Robert Likic, Dusko Kuzmanic
Page
of 8